Dopaminergic Agonists and Receptors: Their Relevance to the Treatment of Parkinson’s Disease

  • D. B. Calne
  • T. A. Larsen
Conference paper


Following the recognition of dopamine as a neurotransmitter, and the discovery of its depletion in parkinsonism, therapy for this disorder has been focused on achieving increased activation of striatal dopaminergic receptors. Initially, this end was accomplished by administering the precursor of dopamine, levodopa; certain unwanted effects of this amino acid, notably nausea and vomiting, were alleviated by concomitant administration of drugs, (carbidopa and benserazide) that blocked the conversion of levodopa to dopamine by L-aromatic amino acid decarboxylase. These enzyme inhibitors were chosen because they did not readily cross the blood-brain barrier, so they did not impede the formation of dopamine in the striatum.


Dopamine Receptor Parkinson Disease Dopamine Agonist Parkinsonian Patient Dopaminergic Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petrie A (1974) Bromocriptine in parkinsonism. Br Med J 4: 442–444PubMedCrossRefGoogle Scholar
  2. Corrodi H, Fuxe K, Hofelt T, Lidbrink P, Ungerstedt U (1973) Effect of ergot drugs on central catecholamine neurons: Evidence for a stimulation of central dopamine neurons. J Pharm Pharmacol 25: 409–412PubMedCrossRefGoogle Scholar
  3. Cotzias GC, Lawrence WH, Papavasiliou PS, Duby SE, Ginos JZ, Mena I (1972) Apomorphine and parkinsonism. Trans Am Neurol Assoc 97: 156–158Google Scholar
  4. Cotzias GC, Papavasiliou PS, Tolosa ES, Méndez JS, Bell-Midura M (1976) Treatment of Parkinson’s disease with aporphines. N Engl J Med 294: 567–572PubMedCrossRefGoogle Scholar
  5. Eisler T, Thorner MO, MacLeod RM, Kaiser DL, Calne DB (1981) Prolactin secretion in Parkinson disease. Neurology (NY) 31: 1356–1359Google Scholar
  6. Flückiger E (1976) The pharmacology of bromocriptine. In: Bayliss RIS, Turner P, Maclay WP (eds) Pharmacological and clinical aspects of bromocriptine (Parlodel) — Proceedings of a symposium held at The Royal College of Physicians, London, 14 May 1976, MCS Consultants, Tunbridge Wells, pp 12–26Google Scholar
  7. Hornykiewicz O (1975) Parkinson’s disease and its chemotherapy. Biochem Pharmacol 24: 1061–1065PubMedCrossRefGoogle Scholar
  8. Hornykiewicz O (1980) Biochemical abnormalities in some extrastriatal neuronal systems in Parkinson’s disease. In: Rinne UK, Klinger M, Stamm G (eds) Parkinson’s disease — Current progress, problems and management, Elsevier/North-Holland, Amsterdam, pp 109–119Google Scholar
  9. Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93–96PubMedCrossRefGoogle Scholar
  10. Klawans HL, Tanner CM, Goetz CG, Glatt S, Nausieda P, Weiner W (1981) Pergolide mesylate therapy in Parkinson’s disease: Report of a 3-month trial in 20 patients. Neurology (NY) 31/2: 133Google Scholar
  11. Lang AE, Quinn N, Brincat S, Marsden CD, Parkes JD (1982) Perolide in late stage Parkinson disease. Ann Neurol 12: 243–247PubMedCrossRefGoogle Scholar
  12. Lee, T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O (1978) Receptor basis for dopaminergic supersensitivity in Parkinson’s disease. Nature 273: 59–61PubMedCrossRefGoogle Scholar
  13. Le Fur G, Meininger V, Baulac M, Phan T, Uzan A (1981) Recepteurs dopaminergiques lymphocytaires et maladie de Parkinson idiopathique. Rev Neurol (Paris) 137: 89–96Google Scholar
  14. LeWitt PA, Ward CD, Larsen TA, Raphaelson MI, Newman RP, Foster N, Dambrosia J, Calne DB (1982a) Comparison of pergolide and bromocripte therapy in parkinsonism. Neurology (NY) 32: A181Google Scholar
  15. LeWitt PA, Gopinathan G, Ward CD, Sanes JN, Dambrosia JM, Durso R, Calne DB (1982b) Lisuride versus bromocriptine treatment in Parkinson disease: A double-blind study. Neurology (NY) 32: 69–72Google Scholar
  16. Lieberman A, Neophytides A, Leibowitz N, et al. (1980) The efficacy of a potent dopamine agonist, lisuride, in Parkinson’s disease (Abstr). Neurology (NY) 30: 366Google Scholar
  17. Lieberman A, Goldstein M, Leibowitz M, Neophytides A, Kupersmith M, Pact V, Kleinberg D (1981) Treatment of advanced Parkinson disease with pergolide. Neurology (NY) 31: 675–682Google Scholar
  18. Parkes JD, Schachter N, Marsden CD, Smith B, Wilson A (1981) Lisuride in parkinsonism. Ann Neurol 9: 48–52PubMedCrossRefGoogle Scholar
  19. Quik M, Spokes EG, Mackay AVP, Bannister R (1979) Alteration in (3H) spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson’s disease. J Neurol Sci 43: 429–437PubMedCrossRefGoogle Scholar
  20. Reisine TD, Fields JZ, Yamamura HI, Bird ED, Spokes E, Schreiner PS, Enna SJ (1977) Neurotransmitter receptor alterations in Parkinson’s disease. Life Sci 21: 335–344PubMedCrossRefGoogle Scholar
  21. Rinne UK, Lonnberg P, Koskinen V (1981) Dopamine receptors in parkinsonian brains. J Neural Transm 51: 97–109PubMedCrossRefGoogle Scholar
  22. Rinne UK (1983) New ergot derivatives in the treatment of Parkinson’s disease. In: Calne DB, McDonald RJ, Horowski R, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New YorkGoogle Scholar
  23. Schwab RS, Amador LV, Lettvin JY (1951) Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc 76: 251–253Google Scholar
  24. Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32: 229–313PubMedGoogle Scholar
  25. Setler PE, Sarau HM, Zerkle CL, Saunders HL (1978) The central effects of a novel dopamine agonist. Eur J Pharmacol 50: 419–430PubMedCrossRefGoogle Scholar
  26. Sokoloff P, Matres MD, Schwartz JP (1980) Three classes of dopamine receptor (D-2, D-3, D-4) identified by binding studies with 3H-apomorphine and 3H-domperidone. Naunyn Schmiedebergs Arch Pharmacol 315: 89–102PubMedCrossRefGoogle Scholar
  27. Spano PF, Govoni S, Trabucchi M (1978) Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. In: Roberts PF, Woodruff GN, Iversen LL (eds) Advances in biochemical psychopharmacology, vol 19. Raven, New York, pp 155–165Google Scholar
  28. Stoof JD, Kebabian JW (1981) Opposing roles for D-l and D-2 dopamine receptors in efflux of cyclinc AMP from rat neostriatum. Nature 294: 366–368PubMedCrossRefGoogle Scholar
  29. Stoof, JD, Kebabian JW (1982) Independent in vitro regulation of D-2 dopamine receptor of dopamine-stimulated efflux of cyclic AMP and K+ stimulated release of acetylcholine from rat neostriatum. Brain Res 250: 263–270PubMedCrossRefGoogle Scholar
  30. Teychenne PF, Jones EA, Ishak KG, Calne DB (1979) Hepatocellular injury with distinctive mitochondrial changes induced by lergotrile mesylate: A dopaminergic ergot derivative. Gastroenterology 76: 575–583PubMedGoogle Scholar
  31. Tsuruta K, Frey EA, Grewe CW, Cote TE, Eskay RL, Kebabian JW (1981) Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor. Nature 292: 463–465PubMedCrossRefGoogle Scholar
  32. Winkler MH, Berl S, Whetsell WO, Yahr MD (1980) Spiroperidol binding in the human caudate nuclear. J Neural Transm (Suppl) 16: 45–51Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • D. B. Calne
  • T. A. Larsen

There are no affiliations available

Personalised recommendations